Trials / Terminated
TerminatedNCT00071552
Efficacy of QVAR vs Flovent Diskus on Small Airways in Poorly Controlled Asthmatic Adolescents/Adult Patients
Evaluation of Clinical Efficacy of HFA-Propelled Beclomethasone Dipropionate Metered-Dose Inhaler Versus Fluticasone Propionate Multidose Dry Powder Inhaler on Small Airways in Poorly Controlled Asthmatic Adolescent and Adult Patients
- Status
- Terminated
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 49 (actual)
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc. · Industry
- Sex
- All
- Age
- 12 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to evaluate the effect of Beclomethasone dipropionate HFA on small airways compared to Fluticasone propionate powder for inhalation administered twice daily to poorly controlled asthmatics.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Qvar | Qvar (HFA-propelled beclomethasone dipropionate metered dose inhaler) 160 mcg twice daily for 12 weeks |
| DRUG | Flovent Diskus | Flovent Diskus (fluticasone propionate multi-dose dry powder inhaler) 200 mcg twice daily for 12 weeks |
Timeline
- Start date
- 2004-01-31
- Primary completion
- 2006-07-31
- Completion
- 2006-07-31
- First posted
- 2003-10-29
- Last updated
- 2021-11-24
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00071552. Inclusion in this directory is not an endorsement.